Zheng Hong, Liu Jia-Yu, Song Feng-Ju, Chen Ke-Xin
Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Hospital and Institute, National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin 300060, China.
Cancer Biol Med. 2013 Sep;10(3):123-30. doi: 10.7497/j.issn.2095-3941.2013.03.001.
Ovarian cancer is one of the most lethal malignant gynecological tumors. More than 70% of patients with ovarian cancer are diagnosed at advanced stage. The 5-year survival in patients with advanced ovarian cancer is less than 30% because of the lack of effective biomarkers for diagnosis, prognosis, and personalized treatment. MicroRNA (miR) is a class of small noncoding RNAs that negatively regulate gene expression primarily through post-transcriptional repression. Many studies on tissue miR in ovarian cancer have been carried out and show great potential in clinical practice. However, tissue samples are not easily available because sampling causes injury. Researchers have started to focus on plasma/serum miR, assuming that blood samples may replace tissue samples in miR research in the future. Plasma/serum miR research is still in its early stages. Studies on its function in the early diagnosis of ovarian cancer have achieved some progress, but plasma/serum miR profiling for prognosis and personalized treatment of ovarian cancer remains unknown. A thorough understanding of the function of plasma/serum miR in ovarian cancer will facilitate early diagnosis and improve treatment for ovarian cancer.
卵巢癌是最致命的妇科恶性肿瘤之一。超过70%的卵巢癌患者在晚期被诊断出来。由于缺乏用于诊断、预后和个性化治疗的有效生物标志物，晚期卵巢癌患者的5年生存率低于30%。微小RNA（miR）是一类小的非编码RNA，主要通过转录后抑制对基因表达进行负调控。关于卵巢癌组织miR的许多研究已经开展，并在临床实践中显示出巨大潜力。然而，由于取样会造成损伤，组织样本不容易获得。研究人员已开始关注血浆/血清miR，推测未来血液样本可能会在miR研究中取代组织样本。血浆/血清miR研究仍处于早期阶段。关于其在卵巢癌早期诊断中的功能研究已取得一些进展，但血浆/血清miR在卵巢癌预后和个性化治疗方面的分析仍不清楚。全面了解血浆/血清miR在卵巢癌中的功能将有助于卵巢癌的早期诊断并改善其治疗。
